文献速递帕金森病与运动障碍

持续皮下输注左旋多巴-卡比多巴(ND0612)治疗伴运动波动的帕金森病的安全性与有效性(BouNDless):一项3期、随机、双盲、双模拟、多中心试验

Safety and efficacy of continuous subcutaneous levodopa-carbidopa infusion (ND0612) for Parkinson's disease with motor fluctuations (BouNDless): a phase 3, randomised, double-blind, double-dummy, multicentre trial.
PubMed 文献 · Lancet Neurol · 2024-03-15

这项3期随机双盲双模拟多中心试验在16个国家117个中心纳入259例伴运动波动的帕金森病患者,比较24小时持续皮下ND0612与口服速释左旋多巴-卡比多巴。ND0612组每日无困扰性异动症的“开”期较口服组多1.72小时(95%CI 1.08至2.36),并改善“关”期等指标,常见不良事件为输注部位反应。

要点

  • ND0612组每日无困扰性异动症的“开”期较口服左旋多巴-卡比多巴组多1.72小时(95%CI 1.08至2.36)。
  • 双盲期ND0612组输注部位反应发生率为57%,口服组为43%。
  • ND0612组有4例严重不良事件与研究治疗相关。

核心结论

  • 3期结果显示,皮下ND0612联合口服速释左旋多巴-卡比多巴可增加无困扰性异动症的“开”期并减少“关”期,具有有利的获益-风险特征。
  • ND0612可能为管理帕金森病运动波动提供一种安全有效的皮下左旋多巴输注方法。
  • 正在进行的开放标签扩展期将提供长期疗效和安全性的进一步信息。

研究设计与样本

  • 3期、随机、双盲、双模拟、活性对照、多中心试验,在16个国家(包括欧洲、以色列和美国)的117个学术和社区神经科站点进行。
  • 纳入年龄≥30岁、诊断帕金森病(“开”期Hoehn和Yahr分期≤3)且每日“关”期至少2.5小时的患者。
  • 患者先经历<12周的开放标签导入期以优化口服速释左旋多巴-卡比多巴和24小时/天皮下ND0612(左旋多巴-卡比多巴60.0/7.5 mg/mL)方案,随后按1:1随机分配至12周双盲治疗。
  • 共筛查381例,随机分配259例(68%),其中ND0612组128例(49%)、口服左旋多巴-卡比多巴组131例(51%);243例(94%)完成研究。

主要发现

  • 主要终点:ND0612组每日无困扰性异动症的“开”期较口服左旋多巴-卡比多巴组多1.72小时(95%CI 1.08至2.36);ND0612组较基线变化为-0.48小时(95%CI -0.94至-0.02),口服组为-2.20小时(95%CI -2.65至-1.74),p<0.0001。
  • 每日“关”期:ND0612组较口服组减少1.40小时(95%CI -1.99至-0.80)。
  • 运动障碍学会-统一帕金森病评定量表第二部分评分:ND0612组较口服组降低3.05分(95%CI -4.28至-1.81)。
  • 患者总体印象变化:OR 5.31(95%CI 2.67至10.58);临床总体印象改善:OR 7.23(95%CI 3.57至14.64)。
  • 双盲期不良事件发生率:ND0612组103/128(80%),口服左旋多巴-卡比多巴组97/131(74%);开放标签ND0612优化期287/322(89%)。

关键数值与推荐

  • 开放标签ND0612优化期输注部位反应266/322(83%);双盲期ND0612组73/128(57%) vs 口服左旋多巴-卡比多巴组56/131(43%)。
  • ND0612组4例严重不良事件与研究治疗相关:输注部位蜂窝织炎(n=2)、输注部位脓肿和输注部位溃疡(n=1)、感觉异常和周围感觉运动神经病(n=1)。
  • ND0612组双盲期1例死亡,与研究治疗无关(跌倒导致创伤性脑损伤)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Conventional oral levodopa therapy for the treatment of Parkinson's disease can be associated with variations in plasma concentrations. Levodopa infusion strategies might provide more consistent drug delivery and fewer motor fluctuations. We aimed to assess the safety and efficacy of a continuous 24 h/day subcutaneous infusion of ND0612 (a levodopa-carbidopa solution) compared with oral immediate-release levodopa-carbidopa for the treatment of motor fluctuations in people with Parkinson's disease. METHODS: We conducted a phase 3, randomised, double-blind, double-dummy, active-controlled, multicentre trial at 117 academic and community neurology sites in 16 countries, including in Europe, Israel, and the USA. Eligible participants were men and women aged 30 years or older with a diagnosis of Parkinson's disease (Hoehn and Yahr stage ≤3 in the on state) who experienced at least 2·5 h/day of off time. Participants underwent an open-label run-in phase (<12 weeks), during which time optimal regimens were established for both oral immediate-release levodopa-carbidopa and for 24 h/day subcutaneous ND0612 infusion (levodopa-carbidopa 60·0/7·5 mg/mL), with supplemental oral levodopa-carbidopa if needed. Participants were then randomly assigned (1:1) to 12 weeks of double-blind treatment with their optimised regimen of either subcutaneous ND0612 or oral levodopa-carbidopa, with matching oral or subcutaneous placebo given as required to maintain blinding. Randomisation was done via an interactive web response system, stratified by region, using a permuted block schedule. Participants, study partners, treating investigators, study site personnel, and the sponsor were masked to treatment group allocation. The primary efficacy endpoint was the change from baseline (ie, time of randomisation, when all patients were receiving an optimised open-label ND0612 regimen) to end of the double-blind phase in total daily on time without troublesome dyskinesia, analysed by intention to treat. This trial is registered with ClinicalTrials.gov, NCT04006210, and is complete. FINDINGS: Between Sept 30, 2019, and April 8, 2022, 381 participants were enrolled, of whom 259 (68%) were randomly assigned, 128 (49%) to subcutaneous ND0612 and 131 (51%) to oral levodopa-carbidopa. 243 (94%) participants completed the study. Treatment with subcutaneous ND0612 provided an additional 1·72 h (95% CI 1·08 to 2·36) of on time without troublesome dyskinesia compared with oral levodopa-carbidopa (change from baseline of -0·48 h [-0·94 to -0·02] with subcutaneous ND0612 vs -2·20 h [-2·65 to -1·74] with oral levodopa-carbidopa; p<0·0001). Significant treatment differences favouring subcutaneous ND0612 were also found in the first four of nine prespecified hierarchical outcomes of daily off time (-1·40 h [95% CI -1·99 to -0·80]), Movement Disorders Society-Unified Parkinson's Disease Rating Scale part II scores (-3·05 [-4·28 to -1·81]), Patients Global Impression of Change (odds ratio [OR] 5·31 [2·67 to 10·58]), and Clinical Global Impression of Improvement (OR 7·23 [3·57 to 14·64]). Hierarchical testing ended after the fourth secondary endpoint. Adverse events were reported by 287 (89%) of 322 participants during open-label ND0612 optimisation, and by 103 (80%) of 128 in the ND0612 group and 97 (74%) of 131 in the oral levodopa-carbidopa group during the double-blind phase. The most common adverse events were infusion-site reactions (266 [83%] participants during open-label ND0612, and 73 [57%] in the ND0612 group vs 56 [43%] in the oral levodopa-carbidopa group during the double-blind phase), most of which were mild. Serious adverse events in four participants in the ND0612 group were related to study treatment (infusion-site cellulitis [n=2], infusion-site abscess and infusion-site ulcer [n=1]; and paraesthesia and peripheral sensorimotor neuropathy [n=1]). One participant in the ND0612 group died during the double-blind phase, but the death was not related to study treatment (fall leading to traumatic brain injury). INTERPRETATION: Results of this phase 3 study showed that subcutaneous ND0612 used in combination with oral immediate-release levodopa-carbidopa increased on time without troublesome dyskinesia and reduced off time, with a favourable benefit-risk profile. ND0612 might offer a safe and efficacious subcutaneous levodopa infusion approach to managing motor fluctuations in people with Parkinson's disease. The ongoing open-label extension phase will provide further information on the long-term efficacy and safety of treatment. FUNDING: NeuroDerm.

来源:Lancet Neurol,查看原文。版权归原作者所有。

引用

  1. Espay AJ, Stocchi F, Pahwa R, et al. Safety and efficacy of continuous subcutaneous levodopa-carbidopa infusion (ND0612) for Parkinson's disease with motor fluctuations (BouNDless): a phase 3, randomised, double-blind, double-dummy, multicentre trial. Lancet Neurol. 2024. PMID: 38499015. doi:10.1016/S1474-4422(24)00052-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。